QOL

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Retrieved on: 
Wednesday, April 24, 2024
CPS, Cancer, DCR, HNSCC, Data collection, QOL, Neck, Pembrolizumab, Merck & Co., CQD, ASX, Fast track (FDA), PD-L1, Data, Autoimmune disease, Incidence, Patient, Head, Death, Quality of life, Merck, Neoplasm, IMM, Medical imaging

SYDNEY, AUSTRALIA, April 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression.

Key Points: 
  • Head and neck squamous cell carcinomas are a heterogenous disease that represent a high unmet medical need regardless of PD-L1 expression.
  • A total of 33 patients with recurrent or metastatic HNSCC have been enrolled into Cohort B.
  • The final number of evaluable patients in Cohort B is expected to be higher and additional data, including complete response rate, will be released together with Cohort A data.
  • Patients in Cohort A are stratified by CPS >1, CPS 1-19, and CPS >20, and the clinical results for these three CPS groups will be evaluated.

Renovion Announces Positive Top-Line Results from Phase 2 CLIMB Study of ARINA-1 (RVN-301) in Patients with Non-Cystic Fibrosis Bronchiectasis

Retrieved on: 
Tuesday, April 30, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hemoptysis, MCID, Inflammation, Safety, Mucus, QOL, Professor, Bronchiectasis, MD, Doctor of Philosophy, Conference, Mycobacterium, Sputum, Periodic breathing, Urinary tract infection, CAAT, Disease, Chronic cough, Patient, Principal, Aes, Diagnosis, Inc., ITT, American Thoracic Society, Quality of life, Asthma, Bronchitis, National Jewish Health, Division, Infection, COPD, Pharmaceutical industry

The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.

Key Points: 
  • The CLIMB study was a randomized double-blind placebo-controlled study to assess the safety and efficacy of ARINA-1 in NCFBE.
  • Participants were randomized (7:3, treatment:placebo), and 40 participants completed the study, with 29 completing in the ARINA-1 arm and 11 in the placebo (0.9% saline) arm.
  • Topline results from the intention-to-treat (ITT) population demonstrate that ARINA-1 is safe and improves quality of life (QOL) in individuals with NCFBE who experience mucus symptoms.
  • Renovion will discuss study results at the American Thoracic Society Meeting (May 17-22) and present findings at the World Bronchiectasis Conference (July 4-6) in Dundee, Scotland.

Asahi Kasei Medical and AW Technologies enter exclusive distribution agreement for TrachFlush in Japan

Retrieved on: 
Wednesday, April 3, 2024
Medical Devices, Health, CE marking, Ventilator-associated pneumonia, Partnership, Patient, AW, Sale, QOL, Workload, Multimedia, ICU, Phlegm, FDA, Marketing

AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.

Key Points: 
  • AW Technologies and Asahi Kasei Medical, a core operating company of the Asahi Kasei Group, have entered into an exclusive distribution agreement in Japan for AW Technologies’ TrachFlush™ device.
  • AW Technologies is currently in the process of medical device registration of the TrachFlush in Japan, with market launch targeted in fiscal 2024.
  • Adam Hansen, CEO of AW Technologies, commented, "We are very pleased and excited to announce our partnership with Asahi Kasei Medical.
  • This partnership is very important for AW Technologies, and Asahi Kasei Medical will play a very important role in our expansion of TrachFlush globally.

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Retrieved on: 
Tuesday, February 20, 2024
Progression-free survival, PFS, QOL, New Drug Application, Physician, Quality of life, Plantar fibromatosis, Patient, OTCQX, NDA, Nursing

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors.
  • ”Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102,” said Kenneth Berlin, President and Chief Executive Officer of Ayala.
  • “There has been a high-level of enthusiasm from clinical trial investigators, support staff, and patients during the enrollment of RINGSIDE.
  • RINGSIDE has been designed as a registration study to support a New Drug Application (NDA) in desmoid tumors.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Non-Postoperative Acute Pain Treatment Market to Exhibit Enormous Growth During the Study Period (2019-2032) | DelveInsight

Retrieved on: 
Friday, January 26, 2024
Patient, Surgery, Infection, Research, Trauma, LAS, Analgesic, Injury, Diagnosis, Pain, Pain management, Rehabilitation, Ice, Nonsteroidal anti-inflammatory drug, Meditation, Anesthetic, USD, Physical examination, Burns, RICE, Lundbeck, QOL, Vertex Pharmaceuticals, Growth, Pharmaceutical industry

LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

Key Points: 
  • LAS VEGAS, Jan. 26, 2024 /PRNewswire/ -- DelveInsight's Non-Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, non-postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.
  • Leading non-postoperative acute pain companies such as Vertex Pharmaceuticals, H. Lundbeck A/S, Satsuma Pharmaceuticals, Axsome Therapeutics, Allodynic Therapeutics, and others are developing novel non-postoperative acute pain drugs that can be available in the non-postoperative acute pain market in the coming years.
  • The non-postoperative acute pain epidemiology section provides insights into the historical and current non-postoperative acute pain patient pool and forecasted trends for the US.
  • To know more about non-postoperative acute pain treatment guidelines, visit @ Non-Postoperative Acute Pain Management
    The dynamics of the non-postoperative acute pain market are expected to change in the coming years.

Snail Games Unleashes ARK: Survival Ascended on PlayStation®5 - Cross-Platform Gameplay and 250+ Mods Await

Retrieved on: 
Thursday, November 30, 2023
Dream, Blue Isle Studios, Quality of life, PlayStation 5, Virtual photography, DLC, Friends, Explosion, Weapon, Xbox, ASA, Survivor, PlayStation, Survival, Steam, Studio Wildcard, QOL, Water, Map, Tree, Creativity, Camera, Video game

This highly-anticipated launch introduces a new group of console players to an expansive world of adventure, complemented by the addition of 250+ mods to enhance gameplay experience.

Key Points: 
  • This highly-anticipated launch introduces a new group of console players to an expansive world of adventure, complemented by the addition of 250+ mods to enhance gameplay experience.
  • Since the October launch of ASA on Steam and Xbox Series X|S more than 1 million gross units have been sold worldwide.
  • Survivors on PlayStation 5 can now jump into freshly launched official servers with increased rates to welcome them onto the Island.
  • As part of our commitment to fostering creativity within the ARK community, Snail, alongside Studio Wildcard are excited to announce the ARKathon Modding Contest in collaboration with Overwolf’s CurseForge.

Centific and Telaid Partner to Bring AI and Computer Vision to Retail

Retrieved on: 
Thursday, December 21, 2023
Quality of life, Partnership, Interest, NRF, CCTV, QSR, AI, QOL, Pitaya, Safety, Emerging technologies, Retail

SEATTLE, Dec. 21, 2023 /PRNewswire/ -- Centific, a global provider of AI and data services, has announced its partnership with Telaid, a North American technology integrator, to bring transformative AI and computer vision solutions to retail and quick-service restaurant (QSR) environments. Effective immediately, Telaid will add Centific's Pitaya.AI computer vision platform to the portfolio of solutions Telaid brings to its customers as experts in in-store retail and QSR technology.

Key Points: 
  • SEATTLE, Dec. 21, 2023 /PRNewswire/ -- Centific, a global provider of AI and data services, has announced its partnership with Telaid , a North American technology integrator, to bring transformative AI and computer vision solutions to retail and quick-service restaurant (QSR) environments.
  • Effective immediately, Telaid will add Centific's Pitaya.AI computer vision platform to the portfolio of solutions Telaid brings to its customers as experts in in-store retail and QSR technology.
  • "Pitaya.AI addresses common retail challenges by enabling businesses to leverage new or existing hardware to its fullest potential," said Jagadish Garimella, Head of Retail and CPG Solutions at Centific.
  • Looking forward, Telaid and Centific are committed to the ongoing development and enhancement of the Pitaya.AI platform's AI and computer vision capabilities.

Health Brand PLAMECA Is Providing Targeted Support Designed to Improve Quality of Life

Retrieved on: 
Thursday, November 30, 2023
Pew Research Center, Urinary tract infection, Mental health, Occupation, Friends, Quality of life, Health, Medicine, QOL, Life, Nursing

FORT LAUDERDALE, Fla., Nov. 30, 2023 /PRNewswire/ -- Quality of life (QOL) is a popular measuring stick for a life well lived. It provides a complex and nuanced metric that a growing number of individuals in the 21st century are using to consider if they are satisfied and happy. PLAMECA is a health brand that is facilitating the pursuit of a good QOL through a wide range of safe, natural, and effective nutraceutical solutions.

Key Points: 
  • PLAMECA Is a Health Brand Providing Multiple Targeted Health Solutions That Fit Each Individual's Needs.
  • FORT LAUDERDALE, Fla., Nov. 30, 2023 /PRNewswire/ -- Quality of life (QOL) is a popular measuring stick for a life well lived.
  • PLAMECA is a health brand that is facilitating the pursuit of a good QOL through a wide range of safe, natural, and effective nutraceutical solutions.
  • Collectively, these enable PLAMECA customers to find targeted and effective natural health solutions that avoid the need to resort to stronger pharmaceutical alternatives.

Multi-center study published in Urology confirms efficacy and safety of Avation Medical's noninvasive Vivally® System for OAB

Retrieved on: 
Wednesday, November 15, 2023
Sale, Calibration, Incontinence, Safety, OAB, Quality of life, Ankle, Patient, FDA, Urinary incontinence, Urination, EMG, Sir Vival, QOL, Diary, Pharmaceutical industry, Dietary supplement, Urology, COLUMBUS

COLUMBUS, Ohio, Nov. 15, 2023 /PRNewswire/ -- Avation Medical, Inc., an innovative neuromodulation and digital health company with a mission to make wearable peripheral neuromodulation accessible to patients across a variety of clinical conditions, today announced the publication of safety and efficacy results from a  multi-center study, "FREEOAB", for its novel Vivally System in Urology, a leading, peer–reviewed journal for urologists.

Key Points: 
  • "In our study, significant reductions in symptom burden were observed at 12 weeks which, notably, persisted out to 12 months, even with a reduction in frequency of therapy sessions."
  • "We are grateful to the investigators and patients that participated in the study for helping us bring the Vivally System to market."
  • Worn on the ankle, Vivally is used at-home with therapy sessions lasting only 30 minutes, as little as once per week.
  • Results of the FREEOAB Study demonstrated significant reductions in three-day diary parameters for daily void, incontinence, and urgency episodes at 12 weeks.